On April 13, 2026, the pancreatic cancer world shifted.
A drug called daraxonrasib — known in trials as RMC-6236 — reported phase 3 results that nearly doubled how long patients lived. Median overall survival was 13.2 months on the drug, compared to 6.7 months on standard chemotherapy. Two weeks later, the U.S. FDA opened expanded access, allowing some American patients to get the drug before it is even formally approved.
I want to explain why this matters. I want to explain what is different about this drug. And I want to explain — honestly — what it will take for a Canadian patient to actually get it.
This one is personal for me. My mom, Heather Cutler, was diagnosed with pancreatic cancer in late 2022. Her tumour had a KRAS G12D mutation. Daraxonrasib targets exactly that kind of mutation. If the timing had been different, she might have been a candidate.
She wasn’t. The science came too late for her. But it has not come too late for everyone, and the Canadians who could benefit deserve to understand what is happening — and what stands between them and this drug.
What Daraxonrasib Is, in Plain Language
Most pancreatic cancers — more than 90% — are driven by a mutated gene called KRAS. For decades, KRAS was considered “undruggable.” Scientists could see it driving the disease. They just could not figure out how to stop it.
Daraxonrasib is one of the first drugs that can. It is a once-daily pill, made by a company called Revolution Medicines. It targets a wide range of KRAS and related RAS mutations — meaning it works for many different patients, not just one narrow subgroup.
The phase 3 trial, called RASolute 302, tested it against standard chemotherapy in patients whose pancreatic cancer had spread and who had already tried one round of treatment. The results were not subtle. Patients on daraxonrasib lived nearly twice as long. The risk of dying was cut by 60%.
Dr. Shubham Pant, one of the oncologists involved in the research, put it this way in an interview with OncLive: we have not seen data like this in pancreatic cancer in over a decade. The last time was when FOLFIRINOX replaced gemcitabine as the standard of care.
For a disease where survival has barely budged in 40 years, this is the closest thing to a breakthrough we have had.
Why This Drug Is Different from Other “Breakthroughs”
You have probably read headlines before about pancreatic cancer “breakthroughs” that turned out to mean very little for actual patients. So let me be specific about why daraxonrasib is different.
First, it is a pill. Standard pancreatic cancer treatment is intravenous chemotherapy — hours in an infusion chair, often with severe side effects. A once-daily pill someone can take at home is a different experience entirely.
Second, it is targeted. Chemotherapy works by attacking fast-growing cells throughout the body. That is why it causes hair loss, nausea, and exhaustion. Targeted therapy goes after a specific feature of the cancer cell. The side effects exist, but they are usually more manageable.
Third, the survival benefit is dramatic. A drug that adds two extra months to life is reported as a success in pancreatic cancer. Daraxonrasib added more than six.
Fourth, the FDA is moving fast. The agency granted the drug Breakthrough Therapy status in 2025. It awarded a National Priority Voucher in October 2025. It granted Orphan Drug status. And on April 30, 2026 — just two days after Revolution Medicines applied — it opened an Expanded Access Program. That two-day turnaround is almost unheard of. It tells you how seriously the FDA is taking this.
So Why Can’t Canadians Just Get It?
Here is where the story gets harder.
In Canada, there are two separate questions about a new drug. The first is whether it is approved for sale. The second is whether anyone will pay for it.
Both questions take a long time.
Step one: Health Canada approval. Before any drug can be sold in Canada, the manufacturer has to file what is called a New Drug Submission with Health Canada. The standard review takes 300 days. A faster Priority Review — used for serious or life-threatening conditions like cancer — takes about 180 days. If everything goes well, Health Canada issues a Notice of Compliance, which is the official approval to sell the drug in Canada.
As of today, Revolution Medicines has not announced a Health Canada submission for daraxonrasib. The company has said it is moving toward “global regulatory submissions,” which usually includes Canada, but the timeline here will trail the U.S. process.
Step two: Health technology assessment. Once Health Canada approves a drug, Canada’s Drug Agency reviews whether the drug should be publicly funded. They look at how well it works, how much it costs, and whether it is good value compared to what already exists. Quebec runs its own version of this through INESSS. This step takes many more months.
Step three: Price negotiation through pCPA. This is the step most Canadians have never heard of. It is also the step that decides whether you can actually get the drug.
The pan-Canadian Pharmaceutical Alliance — pCPA — is a body that negotiates drug prices on behalf of all the provinces, territories, and federal drug plans. The idea is that by negotiating together, the provinces have more power to get better prices than they would on their own. When it works, it saves the system money.
When it does not work, patients pay the price. Sometimes with their lives.
A 2024 analysis showed that on average, it takes nearly two years from Health Canada approval to a drug being publicly listed in even one province. That is two years on top of the time it took to get Health Canada approval in the first place. And listing in one province does not mean listing in all of them. A patient in Newfoundland and a patient in British Columbia can have very different access to the same drug.
What Onivyde Tells Us About What Could Go Wrong
If you want to understand why I am cautious about pancreatic cancer drug access in Canada, you only need to know one word.
Onivyde.
Onivyde is a second-line pancreatic cancer treatment. It was approved by Health Canada in 2017. The pan-Canadian Oncology Drug Review (now part of Canada’s Drug Agency) recommended it for funding in 2018. It was already covered in the United States and several European countries. Clinical data showed it could extend survival by 45%.
In June 2019, pCPA negotiations with the manufacturer ended “without agreement.” The drug went onto a shelf.
It is still on that shelf. As of the most recent public information, Onivyde is not publicly funded anywhere in Canada. Nine years after Health Canada approved it, Canadian pancreatic cancer patients still cannot access it through their provincial drug plans. The negotiations are confidential. The reasons are unclear. What is clear is that Canadian patients have been told, year after year, that an approved second-line treatment exists but they cannot have it.
For a disease where most patients die within a year of diagnosis, “we are still negotiating” is not an answer. It is a sentence.
I think about this every time I read good news about a new pancreatic cancer drug. Approval is one thing. Access is another. They are not the same.
What This Means for Canadians Right Now
If you or someone you love has metastatic pancreatic cancer, here is the honest situation in plain terms:
Daraxonrasib is not yet approved in Canada. The FDA Expanded Access Program is only available through doctors licensed in the United States. A Canadian oncologist cannot enroll a Canadian patient through that program from Canada.
There are still options worth asking your oncologist about. Clinical trials are running globally, including in Canada. Health Canada has a Special Access Program that can sometimes allow physicians to obtain unapproved drugs for patients with serious conditions when no Canadian alternatives exist. These pathways are narrow, and not everyone qualifies. But they exist, and they are worth raising with your care team.
If your tumour has a KRAS mutation, that is information worth knowing. Genomic testing — also called next-generation sequencing — is the way to find out. Access to this kind of testing is uneven across Canada, and that is one of the things we at The Heather Cutler Foundation are working to change.
What Has to Happen Now
Daraxonrasib is a real chance for thousands of Canadian families. Not a cure. Not a miracle. A real, measurable extension of life — at a stage of the disease where every additional month with the people you love is precious beyond words.
For Canadians to actually get this drug, several things have to happen, and we cannot afford for any of them to drag.
Revolution Medicines needs to file with Health Canada quickly. Health Canada needs to use Priority Review to move the file as fast as the science allows. Canada’s Drug Agency needs to recommend it for funding without the months of delay that have become routine. The pCPA needs to negotiate a fair price — and not let those negotiations stall the way Onivyde did. Provinces need to list the drug as soon as a deal is reached.
Every one of those steps has been a chokepoint before. Every one of them can be again.
Mom did not have time. Most pancreatic cancer patients do not have time. The system was not built with the urgency this disease demands, and it has cost lives — including hers.
Daraxonrasib is the most important pancreatic cancer development in over a decade. The question is whether Canada will let its own process turn that breakthrough into another Onivyde.
We are going to be watching this closely. So should you.
The Heather Cutler Foundation is a registered Canadian charity (CRA #743014227 RR 0001) based in Mount Pearl, Newfoundland and Labrador, focused on pancreatic cancer awareness, patient support, and advocacy in Atlantic Canada. To learn more, sign up for updates, or support our work, visit heathercutler.ca.
Information in this article is current as of May 5, 2026. Drug approval and coverage status changes — please check with your healthcare provider for the most current information about your treatment options.
